ClinicalTrials.gov
public full text
Public Domain
Age and Bladder Cancer Outcomes After BCG Treatment: A Multicenter Study
This study investigates whether a patient's age affects the outcomes of Bacillus Calmette-Guérin (BCG) treatment for high-grade bladder cancer. Bladder cancer is a common cancer that can sometimes grow into the deeper layers of the bladder wall. In this study, we focus on patients with primary pT1 high-grade bladder cancer, a form of bladder cancer with a higher risk of coming back or progressing. Standard treatment includes removal of the tumor through the urethra (transurethral resection), a second procedure to check that no tumor remains, and treatment with BCG, which is given directly into the bladder to reduce the risk of the cancer returning or progressing. Current treatment recommendations do not change BCG treatment based on a patient's age. However, some previous studies have suggested that BCG may be less effective in older patients. Because the number of older adults with bladder cancer is increasing, it is important to understand whether age should influence treatment decisions. This is a retrospective multicenter cohort study. Researchers will review medical records of patients with primary pT1 high-grade bladder cancer who underwent transurethral resection, repeat resection showing no remaining tumor, and BCG treatment according to current European Association of Urology (EAU) recommendations. The study will compare cancer outcomes between different age groups. The main outcomes of interest are: Recurrence-free survival: how long patients remain free from a return of bladder cancer. Progression-free survival: how long patients remain free from worsening or more advanced bladder cancer. Overall survival: how long patients remain alive after treatment. The study includes 64 patients, with a median follow-up period of 43 months. Patients were compared using age thresholds of 70 and 75 years. The results showed no significant difference in the risk of cancer recurrence or progression between younger and older patients based on these age thresholds.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer#1057028
- Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer#848631
- QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer#272350
- A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)#1170645
- Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer#848368
Record · ID 836516
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive